COCP Cocrystal Pharma Inc

Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference

Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference

– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST –

BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that the Cocrystal management team, will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12, 2020 at 12:00 PM EST.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A of the presentation will be available on the page of the section of the Company’s website (). The video webcast replay will be made available two hours following the event.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus. Cocrystal employs unique, proprietary, structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit .

Investor and Media Contact:

JTC Team, LLC

(833) 475-8247

###

EN
06/11/2020

Underlying

COCPCocrystal Pharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cocrystal Pharma Inc

 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth V...

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Thursday, October 9, 2025 at 12:00 pm Eastern time (9:00 a.m. Pacific time). The formal presentation will be followed by a hosted question-and-answer session with questions welcomed from the live virtual audience. Those interested in viewing the live...

October 2, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Register...

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or “Cocrystal”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,764,710 shares of its common stock at a ...

September 15, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct O...

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or “Cocrystal”), today announced that it has entered into definitive agreements for the purchase and sale of 2,764,710 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.70 p...

September 12, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Develo...

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral protease inhibitor CDI-988 during a podium presentation at the 9th , held September 7–11, 2025 in Banff, Alberta. Based on a novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represent...

September 12, 2025 1 EN
 PRESS RELEASE
Free
COCP Cocrystal Pharm...

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Ora...

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment There are currently no approved vaccines or treatments for norovirus infectionCocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus infections Phase 1b study is expected to start by year-end 2025 BOTHELL, Wash., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the Company received a Stu...

September 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch